Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Ann Intern Med. 2008 Jul 1;149(1):11-9.

The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: a decision analysis.

Author information

  • 1University of Chicago, Chicago, Illinois 60637, USA. ehuang@medicine.bsd.uchicago.edu

Abstract

BACKGROUND:

Physicians are uncertain about when to pursue intensive glucose control among older patients with diabetes.

OBJECTIVE:

To assess the effect of comorbid illnesses and functional status, mediated through background mortality, on the expected benefits of intensive glucose control.

DESIGN:

Decision analysis.

DATA SOURCES:

Major clinical studies in diabetes and geriatrics.

TARGET POPULATION:

Patients 60 to 80 years of age who have type 2 diabetes and varied life expectancies estimated from a mortality index that was validated at the population level.

TIME HORIZON:

Patient lifetime. Perspective: Health care system.

INTERVENTION:

Intensive glucose control (hemoglobin A1c [HbA1c] level of 7.0) versus moderate glucose control (HbA1c level of 7.9).

OUTCOME MEASURES:

Lifetime differences in incidence of complications and average quality-adjusted days.

RESULTS OF BASE-CASE ANALYSIS:

Healthy older patients of different age groups had expected benefits of intensive glucose control ranging from 51 to 116 quality-adjusted days. Within each age group, the expected benefits of intensive control steadily declined as the level of comorbid illness and functional impairment increased (mortality index score, 1 to 26 points). For patients 60 to 64 years of age with new-onset diabetes, the benefits declined from 106 days at baseline good health (life expectancy, 14.6 years) to 44 days with 3 additional index points (life expectancy, 9.7 years) and 8 days with 7 additional index points (life expectancy, 4.8 years). A similar decline in benefits occurred among patients with prolonged duration of diabetes.

RESULTS OF SENSITIVITY ANALYSIS:

With alternative model assumptions (such as Framingham models), expected benefits of intensive control declined as mortality index scores increased.

LIMITATIONS:

Diabetes clinical trial data were lacking for frail, older patients. The mortality index was not validated for use in predicting individual-level life expectancies. Adverse effects of intensive control were not taken into account.

CONCLUSION:

Among older diabetic patients, the presence of multiple comorbid illnesses or functional impairments is a more important predictor of limited life expectancy and diminishing expected benefits of intensive glucose control than is age alone.

Comment in

PMID:
18591633
[PubMed - indexed for MEDLINE]
PMCID:
PMC2562733
Free PMC Article

Images from this publication.See all images (3)Free text

Figure 1
Figure 2
Figure 3
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems Icon for PubMed Central
    Loading ...
    Write to the Help Desk